Biomarkers Consortium Makes Data From Proteomics Study Available

The Alzheimer’s Disease Neuroimaging Initiative, a $60 million partnership between public and private entities, was formed in 2004 to advance identification of biomarkers capable of monitoring disease progression and improving diagnosis. They announce the release of data from a proteomic-based biomarker study using patient plasma and CSF samples.

Click here to read more.

Share this: